These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26136130)

  • 1. Serum parathyroid hormone concentrations measured by chemiluminescence and electrochemiluminescence methods — are the results comparable in haemodialysis patients with chronic kidney disease?
    Kuczera P; Maszczyk A; Machura E; Kurzak E; Adamczak M; Więcek A
    Endokrynol Pol; 2015; 66(3):219-23. PubMed ID: 26136130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Więcek A
    Endokrynol Pol; 2013; 64(3):176-81. PubMed ID: 23873419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of Serum Total and Free Testosterone Concentrations in Male Chronic Hemodialysis Patients with Secondary Hyperparathyroidism in Response to Cinacalcet Treatment.
    Kuczera P; Adamczak M; Wiecek A
    Kidney Blood Press Res; 2016; 41(1):1-8. PubMed ID: 26751580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
    Ureña-Torres P; Bridges I; Christiano C; Cournoyer SH; Cooper K; Farouk M; Kopyt NP; Rodriguez M; Zehnder D; Covic A
    Nephrol Dial Transplant; 2013 May; 28(5):1241-54. PubMed ID: 23328710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
    Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TREATMENT WITH CINACALCET INCREASES PLASMA ADIPONECTIN CONCENTRATION IN HEMODIALYZED PATIENTS WITH CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYROIDISM.
    Kuczera P; Adamczak M; Machnik G; Okopień B; Wiecek A
    Endocr Pract; 2015 Jul; 21(7):743-9. PubMed ID: 25786554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
    Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
    Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher parathyroid hormone (PTH) concentrations with the Architect PTH assay than with the Elecsys assay in hemodialysis patients, and a simple way to standardize these two methods.
    Monge M; Jean G; Bacri JL; Lemaitre V; Masy E; Joly D; Souberbielle JC
    Clin Chem Lab Med; 2009; 47(3):362-6. PubMed ID: 19199835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid hormone measurement in CKD.
    Souberbielle JC; Roth H; Fouque DP
    Kidney Int; 2010 Jan; 77(2):93-100. PubMed ID: 19812537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
    Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
    Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
    Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
    Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
    Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
    J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Wiecek A
    Clin Endocrinol (Oxf); 2014 Apr; 80(4):607-12. PubMed ID: 24111496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of vitamin C on parathyroid hormone in hemodialysis patients with mild to moderate secondary hyperparathyroidism.
    Sanadgol H; Bayani M; Mohammadi M; Bayani B; Mashhadi MA
    Iran J Kidney Dis; 2011 Nov; 5(6):410-5. PubMed ID: 22057074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel electrochemiluminescence immunoassay exclusively for full-length parathyroid hormone during treatment with cinacalcet for secondary hyperparathyroidism.
    Tanaka H; Komaba H; Koizumi M; Kakuta T; Fukagawa M
    Ther Apher Dial; 2011 Jun; 15 Suppl 1():56-61. PubMed ID: 21595854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A lower proportion of circulating active parathyroid hormone in peritoneal dialysis does not allow the pth inter-method adjustment proposed for haemodialysis.
    González-Casaus ML; González-Parra E; Sánchez-González C; Albalate M; de la Piedra-Gordo C; Fernández E; Torregrosa V; Rodríguez M; Lorenzo V
    Nefrologia; 2014 May; 34(3):330-40. PubMed ID: 24798561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
    O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
    Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.